Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 17   

Articles published

APPY 1.35 0.00 (0.00%)
price chart
Venaxis Announces APPY1 Test Clinical Trial Results to be Presented at ACEP14
CASTLE ROCK, Colo., Oct. 14, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying ...
Related articles »  
Eye Catching Stocks: Hertz Global (NYSE:HTZ), BlackBerry (NASDAQ:BBRY ...
BlackBerry Ltd (NASDAQ:BBRY) return on investment (ROI) is -8.45% while return on equity (ROE) is -8.67%. Venaxis, Inc. (NASDAQ:APPY) on Monday shares closed at $1.68. Venaxis, Inc. (NASDAQ:APPY) monthly performance stands at -5.08% while its ...
Investors Alert: JinkoSolar Holding Co., Ltd. (NYSE:JKS), ARM Holdings plc ...
Venaxis, Inc. (NASDAQ:APPY) announced that results of the company's pivotal APPY1 clinical trial will be presented on 27 October by Dr.
Related articles »  
Watch List: MetLife (NYSE:MET), Twitter Inc (NYSE:TWTR), DSP Group Inc ...
Venaxis, Inc. (NASDAQ:APPY) announced that results of the company's pivotal APPY1 clinical trial will be presented on 27 October by Dr.
Venaxis closes public offering of common shares
Venaxis prices $20 mln public offering of common shares
Venaxis Inc Receives Purchase Order From EMELCA Bioscience